|
| Home : Arch Biopartners Scientists Awarded Funding to Further Develop Brain Tumour Targeting Technology |
|
Jun 24
2011 |
Arch Biopartners Scientists Awarded Funding to Further Develop Brain Tumour Targeting Technology |
|
TORONTO, ONTARIO--(Marketwire - June 23, 2011) - Arch Biopartners Inc. ("Arch" or the "Company") (CNSX:ACH)(OTC:FOIFF) and its subsidiary Arch Cancer Therapeutics ("ACT") today announced Arch scientists Dr. Donna Senger and Dr. Stephen Robbins have been awarded $561,251 of peer reviewed research funding to support ongoing work in the area of malignant glioma and the development of brain tumour cell targeting technology. |
|
|
|
| Source:http://www.marketwire.com/mw/release.do?id=1530837&sourceType=3 |
| |
|
Related News
|
» Acquisition of Securities of Zaruma Resources Inc.
» Stream Announces the Withdrawal of Equity Offering
|
|
|
